MAPT and Alzheimer disease: Prior work from our group has also demonstrated that the SLS is able to differentiate between AD biomarker-defined groups comparably to the in-person administered Auditory Verbal Learning Test (AVLT), including distinguishing participants who were A+ versus A− as well as those who were amyloid and tau positive (A+T+) versus amyloid and tau negative (A−T−) (16).